Press Release Source: Rodman & Renshaw, LLC
Rodman & Renshaw Adds Two Prominent Analysts to Its Life-Sciences Research Team
Tuesday May 3, 1:45 pm ET
NEW YORK--(BUSINESS WIRE)--May 3, 2005--Rodman & Renshaw, LLC today announces the appointment of two prominent healthcare analysts to its life-sciences research team.
Michael G. King, Jr., who is recognized among his peers as one of the sell-side's most authoritative voices on the life-sciences industry, joins Rodman & Renshaw after nearly three years as a managing director and senior biotechnology analyst at Banc of America Securities LLC (BofA). During his tenure at BofA, Mr. King was ranked #11 in the 2004 Institutional Investor All-Star Poll, and also ranked as runner-up in the hedge fund portion of the survey. Prior to BofA, Mr. King served as a managing director and senior biotechnology analyst at Robertson Stephens. He served in a similar capacity for three years at Vector Securities International. Mr. King has also been affiliated with Kidder, Peabody, Hambrecht and Quist, Alex Brown & Sons, and D. Blech and Co. At Rodman & Renshaw, Mr. King will cover a wide variety of life-sciences companies, ranging from micro-cap opportunities to the large-cap industry leaders.
Matthew Murray, Ph.D., CFA, one of the few Wall Street analysts with extensive experience on both the money management and brokerage sides of the industry, also joined the research team at Rodman & Renshaw. Dr. Murray was most recently a portfolio manager and healthcare analyst at Alliance Capital, a position he held for the past six years. Prior to joining Alliance, he was a senior biotechnology analyst at Lehman Brothers and also served in similar capacities at Union Bank of Switzerland, and Alex Brown. Before starting a career on Wall Street, Dr. Murray worked at the National Academy of Sciences and as a staff member in the United States Senate. He graduated first in his class from UC Berkeley to receive his Ph.D. in BioPhysics and has also earned a CFA degree. At Rodman & Renshaw, Dr. Murray will cover a wide variety of life-sciences companies, ranging from micro-cap opportunities to the large-cap industry leaders.
John Borer, President of Rodman & Renshaw, stated, "We are very pleased with the addition of these two renowned analysts in the life-sciences sector to our already well-regarded team of analysts. The collective experience that Michael and Matthew bring to the table will further enhance Rodman & Renshaw's preeminence in the life-sciences sectors."
|
